Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold.
Bsteh G, Hegen H, Krajnc N, Föttinger F, Altmann P, Auer M, Berek K, Kornek B, Leutmezer F, Macher S, Monschein T, Ponleitner M, Rommer P, Schmied C, Zebenholzer K, Zulehner G, Zrzavy T, Deisenhammer F, Di Pauli F, Pemp B, Berger T. Bsteh G, et al. Among authors: zrzavy t. Ann Clin Transl Neurol. 2024 Dec 16. doi: 10.1002/acn3.52279. Online ahead of print. Ann Clin Transl Neurol. 2024. PMID: 39686570 Free article.
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.
Bsteh G, Hoepner R, Gernert JA, Berek K, Gradl C, Kliushnikova D, Damulina A, Traxler G, Föttinger F, Habernig S, Krajnc N, Betancourt AXL, Ponleitner M, Zrzavy T, Deisenhammer F, Di Pauli F, Havla J, Khalil M, Kümpfel T, Wipfler P, Chan A, Berger T, Hammer H, Hegen H. Bsteh G, et al. Among authors: zrzavy t. Eur J Neurol. 2025 Jan;32(1):e16587. doi: 10.1111/ene.16587. Eur J Neurol. 2025. PMID: 39686558 Free PMC article.
Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
Bsteh G, Aicher ML, Walde JF, Krajnc N, Haider L, Traxler G, Gradl C, Salmen A, Riedl K, Poskaite P, Leyendecker P, Altmann P, Auer M, Berek K, Di Pauli F, Kornek B, Leutmezer F, Rommer PS, Zulehner G, Zrzavy T, Deisenhammer F, Chan A, Berger T, Hoepner R, Hammer H, Hegen H. Bsteh G, et al. Among authors: zrzavy t. Neurology. 2024 Sep 24;103(6):e209752. doi: 10.1212/WNL.0000000000209752. Epub 2024 Aug 28. Neurology. 2024. PMID: 39197111
Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
Bsteh G, Hegen H, Krajnc N, Föttinger F, Altmann P, Auer M, Berek K, Kornek B, Leutmezer F, Macher S, Monschein T, Ponleitner M, Rommer P, Schmied C, Zebenholzer K, Zulehner G, Zrzavy T, Deisenhammer F, Di Pauli F, Pemp B, Berger T. Bsteh G, et al. Among authors: zrzavy t. Mult Scler. 2024 Aug;30(9):1128-1138. doi: 10.1177/13524585241267257. Epub 2024 Aug 7. Mult Scler. 2024. PMID: 39109593 Free article.
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.
Friedli C, Krajnc N, Hammer HN, Marti S, Zrzavy T, Evangelopoulos ME, Kapsali I, Rommer P, Berger T, Chan A, Bsteh G, Hoepner R. Friedli C, et al. Among authors: zrzavy t. J Cent Nerv Syst Dis. 2024 May 5;16:11795735241249644. doi: 10.1177/11795735241249644. eCollection 2024. J Cent Nerv Syst Dis. 2024. PMID: 38711956 Free PMC article.
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS.
Zrzavy T, Rieder K, Wuketich V, Thalhammer R, Haslacher H, Altmann P, Kornek B, Krajnc N, Monschein T, Schmied C, Zebenholzer K, Zulehner G, Berger T, Rommer P, Leutmezer F, Bsteh G. Zrzavy T, et al. Front Neurol. 2024 Apr 16;15:1388941. doi: 10.3389/fneur.2024.1388941. eCollection 2024. Front Neurol. 2024. PMID: 38689880 Free PMC article.
61 results